Emmaus Life Science Reports Grant of Endari Market Exclusivity In Kingdom of Saudi Arabia
Emmaus Life Sciences (OTCQB: EMMA) announced that its sickle cell disease treatment, Endari® (L-glutamine oral powder), has been granted market exclusivity in the Kingdom of Saudi Arabia (KSA) by the National Uniform Procurement Agency (NUPCO). The initial exclusivity period is one year, with potential extension to three years upon marketing registration approval.
The exclusivity applies across all KSA government institutions, including Ministry of Health hospitals, Military Hospitals, National Guard, Security Forces, and King Faisal Specialty Hospitals and Research Centers. This represents a significant opportunity in the KSA's healthcare system for treating sickle cell disease patients.
Emmaus Life Sciences (OTCQB: EMMA) ha annunciato che il suo trattamento per la malattia delle cellule falciformi, Endari® (polvere orale di L-glutamina), ha ottenuto l'esclusività di mercato nel Regno dell'Arabia Saudita (KSA) da parte dell'Agenzia Nazionale di Approvvigionamento Uniforme (NUPCO). Il periodo iniziale di esclusività è di un anno, con la possibilità di estensione fino a tre anni in seguito all'approvazione della registrazione per la commercializzazione.
L'esclusività si applica a tutte le istituzioni governative della KSA, inclusi gli ospedali del Ministero della Salute, gli Ospedali Militari, la Guardia Nazionale, le Forze di Sicurezza e gli Ospedali e Centri di Ricerca King Faisal. Questa rappresenta un'opportunità significativa nel sistema sanitario della KSA per il trattamento dei pazienti affetti da malattia delle cellule falciformi.
Emmaus Life Sciences (OTCQB: EMMA) anunció que su tratamiento para la enfermedad de células falciformes, Endari® (polvo oral de L-glutamina), ha obtenido exclusividad en el mercado en el Reino de Arabia Saudita (KSA) por parte de la Agencia Nacional de Adquisiciones Uniformes (NUPCO). El período inicial de exclusividad es de un año, con la posibilidad de extensión a tres años tras la aprobación del registro de comercialización.
La exclusividad se aplica a todas las instituciones gubernamentales de la KSA, incluidos los hospitales del Ministerio de Salud, hospitales militares, la Guardia Nacional, fuerzas de seguridad y los hospitales y centros de investigación King Faisal. Esto representa una oportunidad significativa en el sistema de salud de la KSA para tratar a los pacientes con enfermedad de células falciformes.
Emmaus Life Sciences (OTCQB: EMMA)는 그들의 겸상 적혈구 병 치료제인 Endari® (L-글루타민 경구 분말)가 사우디 아라비아 왕국(KSA)의 국가 통일 조달 기관(NUPCO)으로부터 시장 독점권을 부여받았다고 발표했습니다. 초기 독점 기간은 1년이며, 마케팅 등록이 승인될 경우 3년으로 연장될 수 있습니다.
이 독점권은 KSA의 모든 정부 기관, 즉 보건부 병원, 군 병원, 국가 경호대, 보안군, 킹 파이살 전문 병원 및 연구 센터를 포함하여 적용됩니다. 이는 KSA의 건강 관리 시스템에서 겸상 적혈구 병 환자를 치료할 중요한 기회를 나타냅니다.
Emmaus Life Sciences (OTCQB: EMMA) a annoncé que son traitement pour la maladie des cellules falciformes, Endari® (poudre orale de L-glutamine), a obtenu l'exclusivité de marché dans le Royaume d'Arabie Saoudite (KSA) par l'Agence Nationale d'Approvisionnement Uniforme (NUPCO). La période d'exclusivité initiale est d'un an, avec une possibilité de prolongation de trois ans après approbation de l'enregistrement de commercialisation.
Cette exclusivité s'applique à toutes les institutions gouvernementales de la KSA, y compris les hôpitaux du Ministère de la Santé, les hôpitaux militaires, la Garde nationale, les forces de sécurité et les hôpitaux et centres de recherche King Faisal. Cela représente une opportunité significative dans le système de santé de la KSA pour le traitement des patients atteints de la maladie des cellules falciformes.
Emmaus Life Sciences (OTCQB: EMMA) gab bekannt, dass sein Behandlungsverfahren für die Sichelzellenkrankheit, Endari® (L-Glutamin-Pulver zur Einnahme), im Königreich Saudi-Arabien (KSA) von der Nationalen Einheitlichen Beschaffungsbehörde (NUPCO) die Marktexklusivität gewährt wurde. Die anfängliche Exklusivitätsdauer beträgt ein Jahr, mit der Möglichkeit der Verlängerung auf drei Jahre nach Genehmigung der Vermarktungsregistrierung.
Die Exklusivität gilt für alle staatlichen Institutionen der KSA, einschließlich der Krankenhäuser des Gesundheitsministeriums, Militärkrankenhäuser, die Nationale Garde, Sicherheitskräfte und die King Faisal Spezialkrankenhäuser und Forschungszentren. Dies stellt eine bedeutende Gelegenheit im Gesundheitswesen der KSA dar, um Patienten mit Sichelzellenkrankheit zu behandeln.
- Secured market exclusivity for Endari in Saudi Arabia's government healthcare system
- Potential extension of exclusivity from one to three years upon marketing approval
- Access to large addressable market through all KSA government healthcare institutions
- Marketing registration in KSA still pending approval
- Initial exclusivity period to one year
Initial One-Year Exclusivity Period Will Be Extended to Three Years if Endari is Approved for Marketing
"We are honored and pleased that NUPCO has selected Endari as the exclusive L-glutamine prescription therapy to treat sickle cell disease in the large addressable market of affected patients in KSA's healthcare system," commented Willis Lee, Chairman and Chief Executive Officer of Emmaus.
"While the exclusivity period will be for an initial period of one, we are informed that it will be extended for an additional two years if our pending marketing registration for Endari is approved in the KSA," added Charles W. Stark, Pharm. D., Executive Vice President and Chief Scientific Officer.
About Emmaus Life Sciences
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease. Endari® (L-glutamine oral powder), indicated to reduce the acute complications of sickle cell disease in adults and children 5 years and older, is approved for marketing in
About Endari® (prescription grade L-glutamine oral powder)
Endari®, Emmaus' prescription grade L-glutamine oral powder, was approved by the
Indication
Endari® is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
Important Safety Information
The most common adverse reactions (incidence >10 percent) in clinical studies were constipation, nausea, headache, abdominal pain, cough, pain in extremities, back pain, and chest pain.
Adverse reactions leading to treatment discontinuation included one case each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash.
The safety and efficacy of Endari® in pediatric patients with sickle cell disease younger than five years of age has not been established.
For more information, please see full Prescribing Information of Endari® at: www.ENDARIrx.com/PI.
About Sickle Cell Disease
There are approximately 100,000 people living with sickle cell disease (SCD) in the United States and millions more globally. The sickle gene is found in every ethnic group, not just among those of African descent; and in the United States an estimated 1-in-365 African Americans and 1-in-16,300 Hispanic Americans are born with SCD.1 The genetic mutation responsible for SCD causes an individual's red blood cells to distort into a "C" or a sickle shape, reducing their ability to transport oxygen throughout the body. These sickled red blood cells break down rapidly, become very sticky, and develop a propensity to clump together, which causes them to become stuck and cause damage within blood vessels. The result is reduced blood flow to distal organs, which leads to physical symptoms of incapacitating pain, tissue and organ damage, and early death.2
1Source: Data & Statistics on Sickle Cell Disease – National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, December 2020.
2Source: Committee on Addressing Sickle Cell Disease – A Strategic Plan and Blueprint for Action -- National Academy of Sciences Press, 2020.
Forward-looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the possibility of marketing approval for Endari in the KSA. These forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time, including the company's need to restructure or refinance its existing indebtedness and raise additional funds from related-party loans, third-party loans or other financing to meet its current liabilities and fund its business and operations and doubt about the company's ability to continue as a going concern and other factors disclosed in the company's Annual Report on Form 10-K for the year ended December 31, 2023 and Quarterly Reports on Form 10-Q for the quarter ended September 30, 2024, and actual results may differ materially. Such forward-looking statements speak only as of the date they are made, and Emmaus assumes no duty to update them, except as may be required by law.
Company Contact:
Emmaus Life Sciences, Inc.
Investor Relations
(310) 214-0065
IR@emmauslifesciences.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/emmaus-life-science-reports-grant-of-endari-market-exclusivity-in-kingdom-of-saudi-arabia-302362982.html
SOURCE Emmaus Life Sciences, Inc.
FAQ
What market exclusivity did EMMA receive for Endari in Saudi Arabia?
How long is EMMA's market exclusivity period for Endari in Saudi Arabia?
Which Saudi Arabian healthcare institutions are covered by EMMA's Endari exclusivity?
What conditions must EMMA meet to extend Endari's exclusivity in Saudi Arabia?
